IPO

Onyx Biotec Limited IPO

NSE SME

Listed On: Nov 22, 2024 at ₹ 54.05

₹ 244000 /4000 Shares
*Min Investment

Check Allotment

13 Nov, 2024

Open Date

18 Nov, 2024

Close Date

19 Nov, 2024

Allotment Date

22 Nov, 2024

Listing Date
Onyx Biotec IPO Issue Details
  • Issue Price ₹58-61 per equity share
  • Face Value ₹10 Per Equity Share
  • Total Issue Size 48,10,000 shares(aggregating up to ₹29.34 crore)
  • Fresh Share 48,10,000 shares(aggregating up to ₹29.34 crore)
  • Listing at NSE SME
  • List Price 54.05
  • Listing Date 2024-11-22
  • Lead Manager Horizon Management Private Limited
  • Registrar Mas Services Limited
Market Lot Size

Investors can bid for a minimum of 2000 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

ApplicationLotsSharesAmount
Retail (min)12000₹1,22,000
Retail(max)12000₹1,22,000
NII (min) 24000₹2,44,000
Onyx Biotec IPO Reservation

Onyx Biotec IPO offers total 48,10,000 shares. Out of which 9,12,000 (18.96%) allocated to QIB, 6,88,000 (14.3%) allocated to NII,16,00,000 (33.26%) allocated to RII, NA (NA%) allocated to employees and 13,66,000 (28.4%) allocated to Anchor investors.

Investor CategoryShares OfferedMaximum Allottees
Anchor Investor Shares Offered13,66,000 (28.4%)
Market Maker Shares Offered2,44,000 (5.07%)
QIB Shares Offered9,12,000 (18.96%)
NII (HNI) Shares Offered6,88,000 (14.3%)
Retail Shares Offered16,00,000 (33.26%)
Total Shares Offered48,10,000 (100%)
Onyx Biotec IPO Documents
DRHP
RHP
Onyx Biotec IPO Details


Onyx Biotec Limited IPO is an SME IPO, priced at ₹58-61 per equity share. The equity shares have a face value of ₹10 Per Equity Share each and will be listed on the NSE SME platform. The IPO comprises a total issue of 48,10,000 equity shares, aggregating up to ₹29.34 crores..

The IPO bidding window is open from Nov 13, 2024 to Nov 18, 2024. The allotment is expected to be finalized on Nov 19, 2024, and the tentative listing date is Nov 22, 2024.

The minimum lot size for Retail investors is 2000 shares, with a minimum investment of ₹1,22,000. For HNIs, the minimum application size is 2 lots , amounting to ₹ 2,44,000.

Horizon Management Private Limited is acting as the lead manager to the issue. The registrar of the IPO is Mas Services Limited, and Giriraj Stock Broking Private Limited will act as the market maker for this issue.

Read More
Onyx Biotec IPO Subscription Analysis And Details
Retail
119.36x
Total
198.68x
As onQIB / NIIRetailTotal
Shares Offered / Reserved912,000 / 688,0001,600,0003,200,000
Day 1 13-11-24 06:00 PM
0.00 / 1.70 x5.57 x3.15 x
Day 2 14-11-24 06:00 PM
0.00 / 8.15 x16.40 x9.95 x
Day 3 18-11-24 06:00 PM
32.49 / 603.44 x119.36 x198.68 x
Total No of Applications
1,03,947
Onyx Biotec Valuations
EPS Pre IPO ₹2.28/-
EPS Post IPO ₹4.33/-
P/E Pre IPO 26.81
P/E Post IPO 14.1
ROE 4.99%
ROCE 3.71%
Debt/Equity 1.21
RoNW 4.99%
PAT Margin 12.42
Price to Book Value 3.10
Onyx Biotec Company Financials
In Lakhs
In Lakh
31-Mar-2431-Mar-2331-Mar-22
Assets7,413.585,872.363,683.84
Revenue5,387.433,961.654,498.09
Profit After Tax303.16184.46335.29
Net Worth2,487.871,820.161,637.59
Reserves & Surplus1,155.651,230.001,047.43
Total Borrowing3,078.042,922.831,224.39
About Onyx Biotec Company

Incorporated in the month of May 2005, Onyx Biotec Limited is engaged in the field of pharmaceutical industry with sterile water for injections. The company, currently manufacturing Sterile Water for Injections is also a leading pharmaceutical contract manufacturer providing a holistic portfolio of Dry Powder Injections and Dry Syrups, both to domestic as well as international markets.

The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has the daily production capacity of 638,889 units of Sterile Water for Injections and Unit II makes 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.

Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others are some of the clients for the company.

At the end of May 31, 2024, it had a clientele of over 100 Indian and multinational pharmaceutical companies.

ROHS Certification Private Limited has issued certificates for the management system, ISO 9001:2015 and ISO 14001:2015.

The company, as of July 31, 2024, employs 175 staff across the different departments.

Read More
Onyx Biotec - Promoter(s)

Sanjay Jain

Naresh Kumar

Fateh Pal Singh

Pre Issue Share Holding : 88.60%

Post Issue Share Holding : %

Onyx Biotec IPO - Issue Objectives
1

Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use

2

Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections

3

Prepayment or repayment of all or a portion of certain loans availed by the Company

4

General Corporate Purposes.

Onyx Biotec IPO - Peers Comparison
Company NameEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Onyx Biotec Limited2.282.2818.6726.8112.193.27Standalone
Suven Pharmaceuticals Limited11.811.8375.8283.9214.642.64Consolidated
JB Chemicals35.6635.66188.3753.6318.910.15Consolidated

Notes:

  1. Return on Net Worth (%) = Profit for the year ended March 31, 2023 divided by Total Equity of the Company as on March 31, 2024.
  2. NAV is computed as the company's Total Equity as of March 31, 2023, divided by the outstanding number of equity shares as of March 31, 2024.
Contact Details

Onyx Biotec

Bir Plassi Near Sainimajraropar, Nalagarh Road, District Solan – 174101

+91 172 265 6384

generalinfo@onyxbiotec.com

http://www.onyxbiotec.com/

Registrar Contact Details

Mas Services Limited

(011) 2610 4142

ipo@masserv.com

https://www.masserv.com/opt.asp